Quantum Biopharma plans to file an application by year's end seeking FDA clearance for a Phase 2 clinical trial testing Lucid ...

The number of mitochondrial DNA copies may drop as MS progresses, suggesting a possible biomarker for disease progression, a ...

Copaxone and generic versions of glatiramer acetate are injected under the skin at 20 mg/mL daily or 40 mg/mL three times a ...

It may be largely invisible to others, but the cognitive fog associated with MS can be difficult to manage, says columnist.

Higher levels of a type of bacteria called Lachnospiraceae in the gut may be a key risk factor for multiple sclerosis (MS), ...

Worsening disability may increase the risk of bone mineral density loss in MS, potentially leading to fractures, a study ...

Levels of B-cells can help to predict the risk of disability progression independent of relapse activity in relapsing MS ...

Columnist Susan Payrovi, MD, shares how she's overcoming the shame she once felt as a new doctor diagnosed with a chronic ...

More than $18 million in new research grants and fellowships were awarded toward MS research aligned with its Pathways to ...

People with MS who experience progression independent of relapse activity tend to have more damage to their brain's white ...

Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

Broad rim lesions, which have wider rims of immune cells, are associated with faster disease progression in MS, per a study.